Joel W Neal
Overview
Explore the profile of Joel W Neal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
177
Citations
6568
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2025 Feb;
639(8054):E19.
PMID: 40016449
No abstract available.
2.
Huang Y, Sun Y, Chou H, Wagner N, Vitale M, Bayer A, et al.
Circ Res
. 2025 Feb;
136(5):473-490.
PMID: 39931812
Background: Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardiovascular consequences. Targeted therapies...
3.
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904562
Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its...
4.
Janne P, Wang B, Cho B, Zhao J, Li J, Hochmair M, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401269.
PMID: 39879577
Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III...
5.
Myall N, Whisenant J, Neal J, Iams W, Reckamp K, York S, et al.
JTO Clin Res Rep
. 2025 Jan;
6(2):100757.
PMID: 39866193
Introduction: Although tyrosine kinase inhibitors (TKIs) are effective against NSCLC harboring sensitizing gene mutations, acquired resistance is inevitable. Preclinical studies suggest that combining EGFR TKI and monoclonal antibody therapies may...
6.
Besse B, Goto K, Wang Y, Lee S, Marmarelis M, Ohe Y, et al.
J Thorac Oncol
. 2025 Jan;
PMID: 39755170
Introduction: Treatment options for patients with EGFR-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy are limited. Methods: CHRYSALIS-2 cohort A evaluated amivantamab plus lazertinib in patients...
7.
Waliany S, Nagasaka M, Park L, Lam C, Jiang Z, Lin F, et al.
Cancer Med
. 2024 Dec;
13(24):e70272.
PMID: 39692700
Objectives: Targeted therapies have been shown to improve outcomes in metastatic non-small cell lung cancer (mNSCLC) with driver mutations. We evaluated the real-world prevalence of human epidermal growth factor receptor...
8.
Aredo J, Wakelee H, Ramchandran K, Neal J, Diehn M, Hui A, et al.
JTO Clin Res Rep
. 2024 Dec;
5(12):100741.
PMID: 39624248
Introduction: There are no standard targeted treatment options for advanced -mutant NSCLC beyond G12C inhibitors. A computational model identified regorafenib and low-dose methotrexate as synergistic in preclinical models of -mutant...
9.
Sayegh H, Zagouras A, Neal J, Witteles R, Zhu H, Waliany S
Cardiol Clin
. 2024 Nov;
43(1):31-42.
PMID: 39551560
Hypertension (HTN) has been found to be the most common comorbidity in patients with cancer. In addition to increased prevalence of baseline HTN, patients with cancer may be at increased...
10.
Wu F, Zeng Y, Neal J
Transl Lung Cancer Res
. 2024 Nov;
13(10):2853-2855.
PMID: 39507046
No abstract available.